National Cancer Institute; Notice of Closed Meeting, 42803 [2014-17260]

Download as PDF Federal Register / Vol. 79, No. 141 / Wednesday, July 23, 2014 / Notices Place: National Institutes of Health, Building 31, Room 6C6, 31 Center Drive, Bethesda, MD 20892. Contact Person: Craig A. Jordan, Ph.D., Director, Division of Extramural Activities NIDCD, NIH, Room 8345, MSC 9670, 6001 Executive Blvd., Bethesda, MD 20892–9670, 301–496–8693, jordanc@nidcd.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: https:// www.nidcd.nih.gov/about/Pages/AdvisoryGroups-and-Review-Committees.aspx, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.173, Biological Research Related to Deafness and Communicative Disorders, National Institutes of Health, HHS) Dated: July 17, 2014. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2014–17261 Filed 7–22–14; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES mstockstill on DSK4VPTVN1PROD with NOTICES National Cancer Institute; Notice of Closed Meeting [FR Doc. 2014–17260 Filed 7–22–14; 8:45 am] BILLING CODE 4140–01–P Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2); notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. 17:33 Jul 22, 2014 Jkt 232001 Name of Committee: National Cancer Institute Special Emphasis Panel NCI Experimental Therapeutics Program (Cycle 17 NExT). Date: August 22, 2014. Time: 8:30 a.m. to 4:30 p.m. Agenda: To evaluate the NCI Experimental Therapeutics Program Portfolio. Place: National Institutes of Health, 9000 Rockville Pike, Building 31, Conference Room 6C06, Bethesda, MD 20892. Contact Person: Barbara Mroczkowski, Ph.D., Executive Secretary, Discovery Experimental Therapeutics Program, National Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, MD 20892, (301) 496–4291, mroczkoskib@mail.nih.gov. Joseph Tomaszewski, Ph.D., Executive Secretary, Development Experimental Therapeutics Program, National Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, MD 20892, (301) 496–6711, tomaszej@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: July 17, 2014. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. National Institutes of Health VerDate Mar<15>2010 The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Announcement of Requirements and Registration for ‘‘Stories of Basic Science to Medical Advances’’ Challenge Authority: 15 U.S.C. 3719. The National Institute of General Medical Sciences (NIGMS), one of the components of the National Institutes of Health (NIH), announces a challenge titled ‘‘Stories of Basic Science to Medical Advances.’’ This Challenge aims to track medical advances stemming from NIGMSsupported basic science. SUMMARY: PO 00000 Frm 00049 Fmt 4703 Sfmt 4703 42803 Submission Period: July 21, 2014—October 20, 2014. Judging Period: October 21, 2014— November 20, 2014. Winners announced: 14 days after judging is complete. FOR FURTHER INFORMATION CONTACT: Darren Sledjeski, Ph.D. 301–594–0943, nigms_challenges@mail.nih.gov. SUPPLEMENTARY INFORMATION: The mission of NIGMS is to support basic, non-disease-targeted research that increases understanding of life processes and lays the foundation for advances in disease diagnosis, treatment, and prevention. NIGMSfunded researchers seek to answer important scientific questions to increase our knowledge about the mechanisms and pathways involved in diseases and develop new tools and techniques that have medical applications. NIGMS’ strategic plan states that one of its goals is to ‘‘advance awareness and understanding of the basic biomedical research enterprise, including its value, requirements, and potential impact.’’ Accomplishing this goal, however, can be difficult because the path between basic discoveries and their applications is often long, and the connections can be hard to track. In addition to tracking the medical advances stemming from NIGMSsupported science, the Challenge is also intended to attract more interest and attention to the basic science research funded by NIGMS; stimulate innovation by acknowledging the key role that NIGMS funded research plays in laying the foundation for advances in disease diagnosis, treatment and prevention; and advance the statutory purpose of NIGMS to ‘‘conduct and support research and health information dissemination with respect to general or basic medical sciences and related natural and behavioral sciences which have significance for two or more other national research institutes or are outside the general area of responsibility of any other national research institute.’’ 42 U.S.C. 285k. Subject of Challenge: NIH seeks the public’s help in capturing NIGMS’ progress toward its strategic goal to ‘‘advance awareness and understanding of the basic biomedical research enterprise, including its value, requirements, and potential impact.’’ The goal of the Challenge is to identify past advances that are serving (or have served) to improve human health and well-being but not ongoing studies that may, in the future, have a major impact. NIGMS will use these examples to help inform the historical context of scientific breakthroughs and NIGMS’ DATES: E:\FR\FM\23JYN1.SGM 23JYN1

Agencies

[Federal Register Volume 79, Number 141 (Wednesday, July 23, 2014)]
[Notices]
[Page 42803]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-17260]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2); notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The purpose of this meeting is to evaluate requests 
for preclinical development resources for potential new therapeutics 
for the treatment of cancer. The outcome of the evaluation will provide 
information to internal NCI committees that will decide whether NCI 
should support requests and make available contract resources for 
development of the potential therapeutic to improve the treatment of 
various forms of cancer. The research proposals and the discussions 
could disclose confidential trade secrets or commercial property such 
as patentable material, and personal information concerning individuals 
associated with the proposed research projects, the disclosure of which 
would constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel NCI Experimental Therapeutics Program (Cycle 17 NExT).
    Date: August 22, 2014.
    Time: 8:30 a.m. to 4:30 p.m.
    Agenda: To evaluate the NCI Experimental Therapeutics Program 
Portfolio.
    Place: National Institutes of Health, 9000 Rockville Pike, 
Building 31, Conference Room 6C06, Bethesda, MD 20892.
    Contact Person: Barbara Mroczkowski, Ph.D., Executive Secretary, 
Discovery Experimental Therapeutics Program, National Cancer 
Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, MD 20892, 
(301) 496-4291, mroczkoskib@mail.nih.gov.
    Joseph Tomaszewski, Ph.D., Executive Secretary, Development 
Experimental Therapeutics Program, National Cancer Institute, NIH, 
31 Center Drive, Room 3A44, Bethesda, MD 20892, (301) 496-6711, 
tomaszej@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)


    Dated: July 17, 2014.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2014-17260 Filed 7-22-14; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.